Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer
Dihydromyricetin (DHM) is a natural flavonoid compound extracted from <i>Ampelopsis grossedentata</i> that has been used for centuries in traditional Chinese medicine. DHM has attracted intensive attention due to its numerous beneficial activities, such as hepatoprotection, cardioprotect...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/14/3487 |
| _version_ | 1797407092678590464 |
|---|---|
| author | Jiajun Wu Zuowei Xiao Hongfang Li Neng Zhu Jia Gu Wenmao Wang Chao Liu Wei Wang Li Qin |
| author_facet | Jiajun Wu Zuowei Xiao Hongfang Li Neng Zhu Jia Gu Wenmao Wang Chao Liu Wei Wang Li Qin |
| author_sort | Jiajun Wu |
| collection | DOAJ |
| description | Dihydromyricetin (DHM) is a natural flavonoid compound extracted from <i>Ampelopsis grossedentata</i> that has been used for centuries in traditional Chinese medicine. DHM has attracted intensive attention due to its numerous beneficial activities, such as hepatoprotection, cardioprotection, antioxidant, and anti-inflammation. In addition, DHM inhibits the progression of cancers such as lung cancer, hepatocellular cancer, breast cancer, melanoma, and malignant reproductive systems through multiple mechanisms, including antiangiogenesis, antiproliferation, apoptosis, and inhibition of invasion and migration. Notably, DHM also activates autophagy at different levels, exerting a dual-regulatory effect on cancers. Mechanistically, DHM can effectively regulate mammalian target of rapamycin (mTOR), noncoding RNA-mediated signaling, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, nuclear factor-κB (NF-κB), p53, and endoplasmic reticulum stress (ER stress)-driven signaling in different types of cancers. DHM has also been shown to have inhibitory effects on various regulators that trigger epithelial–mesenchymal transition (EMT). Furthermore, DHM exhibits a remarkable anticancer reversal ability when used in combination with drugs such as adriamycin, nedaplatin, and other drugs. However, the low bioavailability of DHM limits its potential applications, which are improved through structural modification and the exploration of novel dosage forms. Therefore, DHM may become a promising candidate for treating malignancies alone or combined with conventional anticancer strategies used in clinical practice. |
| first_indexed | 2024-03-09T03:36:15Z |
| format | Article |
| id | doaj.art-36dc80c30c5f4bc18586942523342ff0 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T03:36:15Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-36dc80c30c5f4bc18586942523342ff02023-12-03T14:48:03ZengMDPI AGCancers2072-66942022-07-011414348710.3390/cancers14143487Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against CancerJiajun Wu0Zuowei Xiao1Hongfang Li2Neng Zhu3Jia Gu4Wenmao Wang5Chao Liu6Wei Wang7Li Qin8Laboratory of Stem Cell Regulation with Chinese Medicine and Its Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, ChinaLaboratory of Stem Cell Regulation with Chinese Medicine and Its Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, ChinaLaboratory of Stem Cell Regulation with Chinese Medicine and Its Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, ChinaDepartment of Urology, The First Hospital of Hunan University of Chinese Medicine, Changsha 410208, ChinaLaboratory of Stem Cell Regulation with Chinese Medicine and Its Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, ChinaZhangjiajie Meicha Technology Research Center, Hunan Qiankun Biotechnology Co., Ltd., Zhangjiajie 427000, ChinaZhangjiajie Meicha Technology Research Center, Hunan Qiankun Biotechnology Co., Ltd., Zhangjiajie 427000, ChinaTCM and Ethnomedicine Innovation & Development International Laboratory, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, ChinaLaboratory of Stem Cell Regulation with Chinese Medicine and Its Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, ChinaDihydromyricetin (DHM) is a natural flavonoid compound extracted from <i>Ampelopsis grossedentata</i> that has been used for centuries in traditional Chinese medicine. DHM has attracted intensive attention due to its numerous beneficial activities, such as hepatoprotection, cardioprotection, antioxidant, and anti-inflammation. In addition, DHM inhibits the progression of cancers such as lung cancer, hepatocellular cancer, breast cancer, melanoma, and malignant reproductive systems through multiple mechanisms, including antiangiogenesis, antiproliferation, apoptosis, and inhibition of invasion and migration. Notably, DHM also activates autophagy at different levels, exerting a dual-regulatory effect on cancers. Mechanistically, DHM can effectively regulate mammalian target of rapamycin (mTOR), noncoding RNA-mediated signaling, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, nuclear factor-κB (NF-κB), p53, and endoplasmic reticulum stress (ER stress)-driven signaling in different types of cancers. DHM has also been shown to have inhibitory effects on various regulators that trigger epithelial–mesenchymal transition (EMT). Furthermore, DHM exhibits a remarkable anticancer reversal ability when used in combination with drugs such as adriamycin, nedaplatin, and other drugs. However, the low bioavailability of DHM limits its potential applications, which are improved through structural modification and the exploration of novel dosage forms. Therefore, DHM may become a promising candidate for treating malignancies alone or combined with conventional anticancer strategies used in clinical practice.https://www.mdpi.com/2072-6694/14/14/3487dihydromyricetinanticancer activitymultidrug resistance |
| spellingShingle | Jiajun Wu Zuowei Xiao Hongfang Li Neng Zhu Jia Gu Wenmao Wang Chao Liu Wei Wang Li Qin Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer Cancers dihydromyricetin anticancer activity multidrug resistance |
| title | Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer |
| title_full | Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer |
| title_fullStr | Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer |
| title_full_unstemmed | Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer |
| title_short | Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer |
| title_sort | present status challenges and prospects of dihydromyricetin in the battle against cancer |
| topic | dihydromyricetin anticancer activity multidrug resistance |
| url | https://www.mdpi.com/2072-6694/14/14/3487 |
| work_keys_str_mv | AT jiajunwu presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer AT zuoweixiao presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer AT hongfangli presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer AT nengzhu presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer AT jiagu presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer AT wenmaowang presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer AT chaoliu presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer AT weiwang presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer AT liqin presentstatuschallengesandprospectsofdihydromyricetininthebattleagainstcancer |